Clinical Trial Update: Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

A Phase 1 study of Gentulizumab in relapsed/refractory acute myeloid leukemia or myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Gentulizumab (Gentulizumab)

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED